Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2021

01-12-2021 | Metastasis | Research article

Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis

Authors: Hanfang Jiang, Huiping Li

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

Breast cancer (BC) is a leading cause of cancer-related death in females worldwide. Previous studies have demonstrated that matrix metalloproteinases (MMPs) play key roles in metastasis and are associated with survival in various cancers. The prognostic values of MMP2 and MMP9 expression in BC have been investigated, but the results remain controversial. Thus, we performed the present meta-analysis to investigate the associations between MMP2/9 expressions in tumor cells with clinicopathologic features and survival outcome in BC patients.

Methods

Eligible studies were searched in PubMed, Web of Science, EMBASE, CNKI and Wanfang databases. The associations of MMP2/9 overexpression in tumor cells with overall survival (OS), disease-free survival (DFS) and recurrence-free survival (RFS) were assessed by hazard ratio (HR) and 95% confidence interval (CI). The associations of MMP2/9 overexpression with clinicopathological features were investigated by calculating odds ratio (OR) and 95% CI. Subgroup analysis, sensitivity analysis, meta-regression, and analysis for publication bias were performed.

Results

A total of 41 studies comprising 6517 patients with primary BC were finally included. MMP2 overexpression was associated with an unfavorable OS (HR = 1.60, 95% CI 1.33 –1.94, P < 0.001) while MMP9 overexpression predicted a shorter OS (HR = 1.52, 95% CI 1.30 –1.77, P < 0.001). MMP2 overexpression conferred a higher risk to distant metastasis (OR = 2.69, 95% CI 1.35–5.39, P = 0.005) and MMP9 overexpression correlated with lymph node metastasis (OR = 2.90, 95% CI 1.86 – 4.53, P < 0.001). Moreover, MMP2 and MMP9 overexpression were both associated with higher clinical stage and histological grade in BC patients. MMP9 overexpression was more frequent in patients with larger tumor sizes.

Conclusions

Tumoral MMP2 and MMP9 are promising markers for predicting the prognosis in patients with BC.
Appendix
Available only for authorised users
Literature
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRefPubMed
2.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefPubMed
3.
Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J. 2009;15(6):593–602.PubMedCrossRef
4.
Marti JLG, Hyder T, Nasrazadani A, Brufsky AM. The evolving landscape of HER2-directed breast Cancer therapy. Curr Treat Options in Oncol. 2020;21(10):82.CrossRef
5.
Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69(3):562–73.PubMedCrossRef
6.
Raeeszadeh-Sarmazdeh M, Do LD, Hritz BG. Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics. Cells. 2020;9(5):1313.
7.
Vandooren J, Van den Steen PE, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol. 2013;48(3):222–72.PubMedCrossRef
8.
Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000;18(5):1135–49.PubMedCrossRef
9.
Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011;278(1):16–27.PubMedCrossRef
10.
Hojilla CV, Mohammed FF, Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer. 2003;89(10):1817–21.PubMedPubMedCentralCrossRef
11.
Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids. 2011;41(2):271–90.PubMedCrossRef
12.
Deng W, Peng W, Wang T, Chen J, Zhu S. Overexpression of MMPs functions as a prognostic biomarker for Oral Cancer patients: a systematic review and meta-analysis. Oral Health Prev Dent. 2019;17(6):505–14.PubMed
13.
Zhu J, Zhang X, Ai L, Yuan R, Ye J. Clinicohistopathological implications of MMP/VEGF expression in retinoblastoma: a combined meta-analysis and bioinformatics analysis. J Transl Med. 2019;17(1):226.PubMedPubMedCentralCrossRef
14.
Miao C, Liang C, Zhu J, Xu A, Zhao K, Hua Y, Zhang J, Chen W, Suo C, Zhang C, et al. Prognostic role of matrix metalloproteinases in bladder carcinoma: a systematic review and meta-analysis. Oncotarget. 2017;8(19):32309–21.PubMedPubMedCentralCrossRef
15.
Jia H, Zhang Q, Liu F, Zhou D. Prognostic value of MMP-2 for patients with ovarian epithelial carcinoma: a systematic review and meta-analysis. Arch Gynecol Obstet. 2017;295(3):689–96.PubMedCrossRef
16.
Li H, Qiu Z, Li F, Wang C. The relationship between MMP-2 and MMP-9 expression levels with breast cancer incidence and prognosis. Oncol Lett. 2017;14(5):5865–70.PubMedPubMedCentral
17.
Liu Y, Xin T, Jiang QY, Huang DY, Shen WX, Li L, Lv YJ, Jin YH, Song XW, Teng C. CD147, MMP9 expression and clinical significance of basal-like breast cancer. Med Oncol. 2013;30(1):366.PubMedCrossRef
18.
Zhao S, Ma W, Zhang M, Tang D, Shi Q, Xu S, Zhang X, Liu Y, Song Y, Liu L, et al. High expression of CD147 and MMP-9 is correlated with poor prognosis of triple-negative breast cancer (TNBC) patients. Med Oncol. 2013;30(1):335.PubMedCrossRef
19.
Li HC, Cao DC, Liu Y, Hou YF, Wu J, Lu JS, Di GH, Liu G, Li FM, Ou ZL, et al. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat. 2004;88(1):75–85.PubMedCrossRef
20.
Merdad A, Karim S, Schulten HJ, Dallol A, Buhmeida A, Al-Thubaity F, Gari MA, Chaudhary AG, Abuzenadah AM, Al-Qahtani MH. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer: MMP-9 as a potential biomarker for cancer invasion and metastasis. Anticancer Res. 2014;34(3):1355–66.PubMed
21.
Fernandez-Guinea O, Alvarez-Cofino A, Eiro N, Gonzalez LO, del Casar JM, Fernandez-Garcia B, Lamelas ML, Andicoechea A, Vizoso FJ. Low microvascular density at the tumor center is related to the expression of metalloproteases and their inhibitors and with the occurrence of distant metastasis in breast carcinomas. Int J Clin Oncol. 2013;18(4):629–40.PubMedCrossRef
22.
Sullu Y, Demirag GG, Yildirim A, Karagoz F, Kandemir B. Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast. Pathol Res Pract. 2011;207(12):747–53.PubMedCrossRef
23.
Rahko E, Jukkola A, Melkko J, Paavo P, Bloigu R, Talvensaari-Mattila A, Turpeenniemi-Hujanen T. Matrix metalloproteinase-9 (MMP-9) immunoreactive protein has modest prognostic value in locally advanced breast carcinoma patients treated with an adjuvant antiestrogen therapy. Anticancer Res. 2004;24(6):4247–53.PubMed
24.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–12.PubMedCrossRef
25.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.PubMedCrossRef
26.
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.PubMedPubMedCentralCrossRef
27.
Joseph C, Alsaleem M, Orah N, Narasimha PL, Miligy IM, Kurozumi S, Ellis IO, Mongan NP, Green AR, Rakha EA. Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival. Breast Cancer Res Treat. 2020;182(2):267–82.PubMedPubMedCentralCrossRef
28.
Yang J, Min KW, Kim DH, Son BK, Moon KM, Wi YC, Bang SS, Oh YH, Do SI, Chae SW, et al. High TNFRSF12A level associated with MMP-9 overexpression is linked to poor prognosis in breast cancer: gene set enrichment analysis and validation in large-scale cohorts. PLoS One. 2018;13(8):e0202113.PubMedPubMedCentralCrossRef
29.
Ramos EA, Silva CT, Manica GC, Pereira IT, Klassen LM, Ribeiro EM, Cavalli IJ, Braun-Prado K, Lima RS, Urban CA, et al. Worse prognosis in breast cancer patients can be predicted by immunohistochemical analysis of positive MMP-2 and negative estrogen and progesterone receptors. Rev Assoc Med Bras (1992). 2016;62(8):774–81.CrossRef
30.
31.
Youssef NS, Hakim SA. Association of Fascin and matrix metalloproteinase-9 expression with poor prognostic parameters in breast carcinoma of Egyptian women. Diagn Pathol. 2014;9:136.PubMedPubMedCentralCrossRef
32.
Min KW, Kim DH, Do SI, Kim K, Lee HJ, Chae SW, Sohn JH, Pyo JS, Oh YH, Kim WS, et al. Expression patterns of stromal MMP-2 and tumoural MMP-2 and -9 are significant prognostic factors in invasive ductal carcinoma of the breast. APMIS. 2014;122(12):1196–206.PubMedCrossRef
33.
Tang D, Piao Y, Zhao S, Mu X, Li S, Ma W, Song Y, Wang J, Zhao W, Zhang Q. Expression and correlation of matrix metalloproteinase-9 and heparanase in patients with breast cancer. Med Oncol. 2014;31(7):26.PubMedCrossRef
34.
Wu QW, Yang QM, Huang YF, She HQ, Liang J, Yang QL, Zhang ZM. Expression and clinical significance of matrix metalloproteinase-9 in lymphatic invasiveness and metastasis of breast cancer. PLoS One. 2014;9(5):e97804.PubMedPubMedCentralCrossRef
35.
Puzovic V, Brcic I, Ranogajec I, Jakic-Razumovic J. Prognostic values of ETS-1, MMP-2 and MMP-9 expression and co-expression in breast cancer patients. Neoplasma. 2014;61(4):439–46.PubMedCrossRef
36.
Zeng Y, Liu C, Dong B, Li Y, Jiang B, Xu Y, Meng L, Wu J, Qu L, Shou C. Inverse correlation between Naa10p and MMP-9 expression and the combined prognostic value in breast cancer patients. Med Oncol. 2013;30(2):562.PubMedCrossRef
37.
Ranogajec I, Jakic-Razumovic J, Puzovic V, Gabrilovac J. Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients. Med Oncol. 2012;29(2):561–9.PubMedCrossRef
38.
Zhang B, Cao X, Liu Y, Cao W, Zhang F, Zhang S, Li H, Ning L, Fu L, Niu Y, et al. Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer. BMC Cancer. 2008;8:83.PubMedPubMedCentralCrossRef
39.
Wu ZS, Wu Q, Yang JH, Wang HQ, Ding XD, Yang F, Xu XC. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer. 2008;122(9):2050–6.PubMedCrossRef
40.
Hao L, Zhang C, Qiu Y, Wang L, Luo Y, Jin M, Zhang Y, Guo TB, Matsushima K, Zhang Y. Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer. Cancer Lett. 2007;253(1):34–42.PubMedCrossRef
41.
Mylona E, Nomikos A, Magkou C, Kamberou M, Papassideri I, Keramopoulos A, Nakopoulou L. The clinicopathological and prognostic significance of membrane type 1 matrix metalloproteinase (MT1-MMP) and MMP-9 according to their localization in invasive breast carcinoma. Histopathology. 2007;50(3):338–47.PubMedCrossRef
42.
Zhou S, Liu C, Wu SM, Wu RL. Expressions of CD147 and matrix metalloproteinase-2 in breast cancer and their correlations to prognosis. Ai Zheng. 2005;24(7):874–9.PubMed
43.
Sivula A, Talvensaari-Mattila A, Lundin J, Joensuu H, Haglund C, Ristimaki A, Turpeenniemi-Hujanen T. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat. 2005;89(3):215–20.PubMedCrossRef
44.
Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer. 2003;89(7):1270–5.PubMedPubMedCentralCrossRef
45.
Fan SQ, Wei QY, Li MR, Zhang LQ, Liang QC. Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma. Ai Zheng. 2003;22(9):968–73.PubMed
46.
Nakopoulou L, Tsirmpa I, Alexandrou P, Louvrou A, Ampela C, Markaki S, Davaris PS. MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival. Breast Cancer Res Treat. 2003;77(2):145–55.PubMedCrossRef
47.
Hirvonen R, Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) in T(1-2)N0 breast carcinoma. Breast Cancer Res Treat. 2003;77(1):85–91.PubMedCrossRef
48.
Djonov V, Cresto N, Aebersold DM, Burri PH, Altermatt HJ, Hristic M, Berclaz G, Ziemiecki A, Andres AC. Tumor cell specific expression of MMP-2 correlates with tumor vascularisation in breast cancer. Int J Oncol. 2002;21(1):25–30.PubMed
49.
Talvensaari-Mattila A, Paakko P, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy. Breast Cancer Res Treat. 2001;65(1):55–61.PubMedCrossRef
50.
Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma. Breast Cancer Res Treat. 1999;58(3):287–93.PubMedCrossRef
51.
Talvensaari-Mattila A, Paakko P, Hoyhtya M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer. 1998;83(6):1153–62.PubMedCrossRef
52.
Ban SY, Tan XX, Qiao JJ. The relationship between MMP-2 and TIMP2 expression and metastasisi and prognosis of breat infiltrative ductal cancer. J Postgrad Med. 2004;27(6):27–9.
53.
Zhao JX, Lin MZ, Yao HW, Wan YL. The expression of transferrin and MMP-9 in breast cancer and its significance in prognosis. Chin J Clin Oncol. 2008;35(1):22–5.
54.
Zhou N, Tan XS, Xu TT, Wang FR, Hu SY. Expression of RECK and MMP9 proteins in triple negative breast cancer and the relationship with clinical characteristics and prognosis. Oncol Progress. 2019;17(16):1942–5.
55.
Huang S, Chen J, Jia YJ, Wang YK, Lu YS, Wu KJ. Research on the correlation of MMP9 and P53 expression with the prognosis of triple negative breast cancer. Progress Modern Biomed. 2014;14(5):881–4.
56.
Zhang J, Yao SH, Wang XH. Expression of CD147 and matrix metalloproteinases 9 in triple-begative creast cancer before neoadjuvant chemotherapy and its guiding significance. Eval Anal Drug-Use Hospit China. 2019;19(11):1321–3.
57.
Scorilas A, Karameris A, Arnogiannaki N, Ardavanis A, Bassilopoulos P, Trangas T, Talieri M. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br J Cancer. 2001;84(11):1488–96.PubMedPubMedCentralCrossRef
58.
Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res. 2004;10(22):7621–8.PubMedCrossRef
59.
Bottino J, Gelaleti GB, Maschio LB, Jardim-Perassi BV, Zuccari DA. Immunoexpression of ROCK-1 and MMP-9 as prognostic markers in breast cancer. Acta Histochem. 2014;116(8):1367–73.PubMedCrossRef
60.
Dofara SG, Chang SL, Diorio C. Gene polymorphisms and circulating levels of MMP-2 and MMP-9: a review of their role in breast Cancer risk. Anticancer Res. 2020;40(7):3619–31.PubMedCrossRef
61.
Jezierska A, Motyl T. Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit. 2009;15(2):RA32–40.PubMed
62.
Brown GT, Murray GI. Current mechanistic insights into the roles of matrix metalloproteinases in tumour invasion and metastasis. J Pathol. 2015;237(3):273–81.PubMedCrossRef
63.
Darlix A, Lamy PJ, Lopez-Crapez E, Braccini AL, Firmin N, Romieu G, Thezenas S, Jacot W. Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases? Int J Cancer. 2016;139(10):2299–311.PubMedCrossRef
64.
Kuvaja P, Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. Low serum level of pro-matrix metalloproteinase 2 correlates with aggressive behavior in breast carcinoma. Hum Pathol. 2006;37(10):1316–23.PubMedCrossRef
65.
Talvensaari-Mattila A, Turpeenniemi-Hujanen T. Preoperative serum MMP-9 immunoreactive protein is a prognostic indicator for relapse-free survival in breast carcinoma. Cancer Lett. 2005;217(2):237–42.PubMedCrossRef
66.
Leppa S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I. A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin Cancer Res. 2004;10(3):1057–63.PubMedCrossRef
67.
Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol. 2003;200(4):448–64.PubMedCrossRef
68.
Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene. 2000;19(56):6642–50.PubMedCrossRef
69.
Stuelten CH, DaCosta BS, Arany PR, Karpova TS, Stetler-Stevenson WG, Roberts AB. Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta. J Cell Sci. 2005;118(Pt 10):2143–53.PubMedCrossRef
70.
Singer CF, Kronsteiner N, Marton E, Kubista M, Cullen KJ, Hirtenlehner K, Seifert M, Kubista E. MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions. Breast Cancer Res Treat. 2002;72(1):69–77.PubMedCrossRef
71.
72.
Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, van de Vijver MJ. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007;9(5):R65.PubMedPubMedCentralCrossRef
Metadata
Title
Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis
Authors
Hanfang Jiang
Huiping Li
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-07860-2

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue

Research

Comparison of the analgesic effect of ultrasound-guided paravertebral block and ultrasound-guided retrolaminar block in Uniportal video-assisted Thoracoscopic surgery: a prospective, randomized study

Research article

Co-expression of low-risk HPV E6/E7 and EBV LMP-1 leads to precancerous lesions by DNA damage

Research

Efficacy of systemic oncological treatments in patients with advanced esophageal or gastric cancers at high risk of dying in the middle and short term: an overview of systematic reviews

Research

Colorectal cancer survival among Ministry of National Guard-Health Affairs (MNG-HA) population 2009–2017: retrospective study

Research

Incidence, mortality and survival in malignant pleural mesothelioma before and after asbestos in Denmark, Finland, Norway and Sweden

Research

Intralesional injection of rose bengal augments the efficacy of gemcitabine chemotherapy against pancreatic tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits